Detailed instructions for use of adagrasibu

1. Overview of drugs

Adagrasib (Adagrasib), as an innovative anti-cancer drug, has been approved by the FDA, specifically for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) confirmed by genetic testing to carry the KRAS G12C mutation. This indication is established under the accelerated approval mechanism based on objective response rate (ORR) and duration of response (DOR). Further confirmatory trials are needed in the future to confirm its long-term clinical benefit.

2. Applicable groups and diseases

Adagrasib is suitable for adult patients with locally advanced or metastatic non-small cell lung cancer who have been confirmed to carry KRAS G12C mutations by testing methods approved by the FDA and have received at least one systemic therapy.

3. Drug side effects

While taking adagrasib, patients may experience some common side effects, including but not limited to nausea, diarrhea, vomiting, fatigue, musculoskeletal pain, hepatotoxicity, renal impairment, edema, and dyspnea. At the same time, some laboratory index abnormalities may also occur, such as lymphopenia, hemoglobin decrease, etc. Patients should pay close attention to physical changes during medication and seek medical attention immediately if there are any abnormalities.

4. Medication methods and dosage

The recommended dose of adagrasiib is 600 mg orally twice daily until disease progression or intolerable toxicity occurs. There is no need to consider diet when taking the medicine. It is recommended to swallow the tablets whole and avoid chewing, crushing or dividing. If vomiting occurs after taking the medicine, there is no need to take another dose, just continue taking the next medicine at the planned time. If you miss a dose unintentionally and it is more than 4 hours before the next dose, you should skip this dose and continue taking the medication as planned.

5. Drug storage

Adagarasib should be stored at room temperature, i.e. 20°C to 25°C (68°F to 77°F), with an allowed temperature fluctuation range of 15°C to 30°C (59°F to 86°F). Please ensure the storage environment is dry, dark and away from children.

6. Mechanism of action

Adagrasib acts as an irreversible inhibitor of KRAS G12C by covalently binding to the mutated cysteine in KRAS G12C, locking the mutated KRAS protein in an inactive state, thereby blocking downstream signaling, thereby inhibiting the growth and viability of tumor cells. This process does not affect the function of wild-type KRAS protein, demonstrating its high selectivity.

7. Overtreatment

Specific information regarding adagrasib overdose is not yet complete. However, overdose may increase the patient's risk of serious adverse reactions, such as liver toxicity, gastrointestinal adverse reactions, and QTc interval prolongation. In the event of overdose, seek medical attention immediately and take necessary symptomatic support measures according to the doctor's advice.

8. Taboo groups

This drug is contraindicated in patients who are allergic to adagrasib or any of its components. In addition, animal studies have shown that adagrasib may cause fertility damage in both men and women of childbearing potential. Therefore, patients should follow the guidance of their doctor during treatment and be aware of possible fertility risks.